Objective To compare the effectiveness of corticosteroid injections to local anaesthetic injections in the management of rotator cuff-related shoulder pain (RCRSP). Design Systematic review with best evidence synthesis. Data sources The Cochrane, PubMed, CINAHL Plus, PEDro and EMBASE electronic databases were searched (inception until 8 June 2017). Reference lists of included articles were also hand searched. Eligibility criteria Two reviewers independently evaluated eligibility. Randomised controlled trials (RCTs) were included if they compared subacromial injections of corticosteroid with anaesthetic injections. Two reviewers independently extracted data regarding short-term, midterm and long-term outcomes for pain, self-reported function, range of motion and patient-perceived improvement. Results Thirteen RCTs (n=1013) were included. Four trials (n=475) were judged as being at low risk of bias.
bACkgROunD
Shoulder pain is a common musculoskeletal disorder with prevalence estimates ranging from 6.9% to 26.0% for point prevalence, annual prevalence of 4.7%-46.7% and lifetime prevalence of 6.7%-66.7%. 1 Prevalence increases with age, 2 and shoulder pain is frequently associated with longterm disability. [3] [4] [5] Injection therapy is a common intervention for musculoskeletal shoulder pain and is administered in primary and secondary care. In the UK, general practitioners administer corticosteroid (CS) injections to approximately 1 in 10 people presenting with shoulder pain in primary care. 3 Injection therapy for shoulder pain is also performed by physiotherapists, orthopaedic surgeons, rheumatologists, radiologists, sports and exercise medicine doctors and others in primary and secondary care, as well as in private settings. However, the definitive number of people receiving CS injections for musculoskeletal shoulder conditions remains unknown.
Rotator cuff-related shoulder pain (RCRSP) 6 is an overarching clinical term and includes a number of other conditions: subacromial impingement syndrome, 7 subacromial pain syndrome 8 and rotator cuff tendinopathy. 9 10 In addition to local tissue pathology, persistent pain associated with RCRSP may be related to altered processing and output of the central nervous system. 11 12 Education, advice and exercise are the most common treatments for RCRSP 6 and have comparable results to surgery. 6 13 Another very common treatment for this condition is injection therapy, which typically involves injections of CS in isolation, or more commonly, mixed with anaesthetic 14 into the subacromial space. 15 For patients with RCRSP, CS or CS and anaesthetic preparations are often administered for treatment, 3 and anaesthetic injections alone are used for diagnosis, in a procedure known as the Neer impingement test. 7 Although CS injections for RCRSP are common, the definitive mechanism of action is uncertain, with suggestions that they may have an anti-inflammatory role, 16 reduce tenocyte numbers 17 and inhibit nociceptor activity. 18 There is also uncertainty regarding clinical effectiveness with previous reviews suggesting their benefit maybe unclear, 19 20 short lived, [21] [22] [23] no greater than non-steroidal anti-inflammatories 21 22 or beneficial for up to 9 months. 24 In addition, there is emerging evidence linking the use of CS injections with negative effects on rotator cuff tissue. [25] [26] [27] Due to these risks, anaesthetic-only injections (although not devoid of risk) might, when deemed appropriate, be considered a reasonable alternative to CS in the management of RCRSP. 6 A recently published meta-analysis assessed short-term outcomes and concluded that CS injections provide, at best, a minimal transient pain reduction in a small number of patients with rotator cuff tendinosis. 23 No previous review has directly compared CS alone, or CS and anaesthetic injections, with local anaesthetic-alone injections in the treatment of RCRSP. A comparison of this nature is relevant for a number of reasons, including the common use of injection therapy in the management of RCRSP, Review as well as: (1) the potential comparable clinical effectiveness of these medicines 14 and (2) the potential deleterious effect of CS on tendon tissue. 26 To inform the shared decision-making process, those seeking and providing treatment for RCRSP would be better informed with more knowledge on injection therapy, especially comparing the most commonly performed procedures (CS alone or CS and anaesthetic injections, with local anaesthetic-alone injections) in the management of RCRSP. Therefore, the aim of this review was to compare these pharmacological preparations in the management of RCRSP for clinical effectiveness (symptoms, range of movement and function) in the short term, medium term and long term.
METhODs
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Cochrane collaboration guidelines were followed. [28] [29] [30] PROSPERO registration number: CRD42016033161.
Population
Inclusion criteria: studies with adult participants diagnosed with RCRSP were included. 6 Exclusion criteria: participants with non-RCRSP shoulder conditions such as shoulder dislocation or instability, fractures, rheumatological conditions or frozen shoulder. Also, people who had undergone previous surgery, as well as those with confirmed full thickness rotator cuff tears.
Intervention/control
Inclusion criteria: randomised clinical trials. Studies were included if they compared groups receiving single or repeated: subacromial injections of CS with or without local anaesthetic versus local anaesthetic injection without CS. Concurrent prescription of exercise therapy, as well as prescription of pain relieving medications, such as analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), was permitted inclusions, as this reflects common clinical management of RCRSP. 6 31 Exclusion criteria: in the treatment of RCRSP, the subacromial space is the most common target for injections, and investigations of injection therapy that did not solely target this region 32 33 were excluded. Other injection procedures, such as barbotage, were also excluded.
Outcome
Outcome measures included shoulder pain, self-reported function, range of motion and patient-perceived improvement. Follow-up time postintervention was defined as short term (less than 3 months), midterm (3-12 months) and long term (a year or longer).
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Data sources
The Cochrane Library, PubMed, EMBASE, PEDro and 'CINAHL plus' databases were searched from inception to 8 June 2017 by two independent reviewers (TC and MM). No language, date or publication restrictions were applied. Search terms included 'shoulder', 'impingement', 'subacromial', 'injections', 'corticosteroid' and 'local anaesthetic'. These terms were linked broadly to the population, intervention, comparators and outcome elements for the review question (table 1) .
The reference lists of retrieved articles, including previous systematic reviews, were assessed for additional study titles and relevant publications, including articles not identified in the search, personal communications, books and book chapters.
study selection
Studies that were not randomised controlled trials (RCTs) were excluded from the review. Selection of studies was independently performed by two reviewers (TC and MM). Where full-text manuscripts were not accessible, the corresponding authors were contacted. If there was no reply or the full text was not available, the study was excluded from this review. Following this process (and after a 1-month wait), two studies were excluded from the review as only abstracts of these studies have been published. 35 36 Two eligible studies 37 38 not published in the English language were professionally translated into English by bilingual members of the Cochrane collaboration.
Data extraction
Data were independently extracted by two reviewers (TC and MM) using the Cochrane data extraction form for RCT intervention reviews (http:// training. cochrane. org/ resource/ datacollection-forms-intervention-reviews). Any discrepancies in this process were resolved by discussion between the two reviewers, followed by reassessment of the data. A system to resolve any disagreements was established a priori via discussion with a third reviewer (JL), but no such discrepancies occurred. Data Review extraction for the two non-English studies were performed by the bilingual members of the Cochrane collaboration.
Risk of bias assessment
Two reviewers independently assessed risk of bias using the domain-based Cochrane tool for RCTs (see table 2 and figure 1 ). Trials were evaluated as low risk of bias if all individual criteria were low and high if at least one was rated as high (and that criterion was deemed by the reviewers to introduce bias). For further information on this tool, please refer to the Cochrane collaboration handbook. 39 Exceptions were made if a specific criterion was rated as being of high risk of bias but this was judged, by the reviewers, not to influence or affect the overall risk of bias.
For example, if a clinician performing the injections in a study was not blind to the treatment but the patient was blinded, and blind outcome assessment was used, then the overall risk of bias would be scored as low. Items rated as unclear raised the risk of bias. 39 An overall risk of bias rating for each trial was agreed by two reviews (TC and MM). Table 3 details pharmacological information and injection method relating to the studies deemed to be at low risk of bias. A system to resolve any disagreements was established a priori via discussion with a third reviewer (JL). Three such disagreements occurred during the risk of bias assessment, and consensus was agreed by discussion following review of the data. Further discussion with the third reviewer was therefore not required.
Data extraction and risk of bias assessment procedures were pilot-tested by TC and MM on three similar articles prior to the formal review process. 40 A Cohen's kappa coefficient was used to assess inter-rater reliability for judgement of high and low risk of bias for each criterion. The number of agreements was 36/39 (92.31%) with a Kappa score of 0.836 and thus the level of agreement was considered strong. 41 
Data syntheses
The studies included in our review used different medications, doses and outcome measures (see online supplementary table 1). Due to these confounding variables, a decision not to pool data to perform a meta-analysis was reached. Instead, we used a best evidence synthesis to synthesise the results following data extraction and assessment of risk of bias. Textual descriptions of studies were written to aid the synthesis of findings, and tables were used to present study characteristics, data extraction and risk of bias assessments. Studies were grouped in accordance with their level of risk of bias in order to identify those assessed as having the highest level of internal validity.
The best evidence synthesis was based on the quality of the studies reviewed 42 : ► Strong evidence: provided by generally consistent findings in multiple high quality RCTs. ► Moderate evidence: provided by generally consistent findings in one high-quality RCT plus one or more low-quality RCTs, or by generally consistent findings in multiple low quality RCTs. ► Limited or conflicting evidence: only one RCT (either high or low quality) or inconsistent findings in multiple RCTs. ► No evidence: no RCTs.
To guide clinical recommendations, studies were combined in relation to their outcome timescales 34 and whether their results favoured CS, local anaesthetic or neither injection type.
REsulTs
The electronic database search, performed on 8 June 2017, identified 286 potentially eligible articles. Hand searches of relevant reference lists identified one further article, making a total of 287 potentially eligible articles. Ultimately, 13 full-text studies were included in this systematic review, and seven studies were excluded. 35 36 43-47 Figure 2 details the PRISMA flow chart.
short-term comparisons (0-12 weeks)
Twelve studies assessed short-term (0-12 weeks) outcomes of injection therapy for RCRSP. Five of the 12 studies, four of high risk of bias 38 48-50 and one of low risk of bias, 51 reported in favour of CS injections for a range of different outcome measures (table 3) .
Three further studies, one of high risk of bias 52 and two of low risk of bias, 53 54 reported improvements in the first 4-6 weeks in favour of CS but reported no significant difference between groups at 12 weeks. The remaining four studies, three of high risk of bias 37 55 56 and one of low risk of bias, 14 reported no significant difference in short-term outcomes between the two types of injection therapy at any time point.
In summary, three trials 51 53 54 (n=417) of low risk of bias favoured CS injections for the first 4-8 weeks post-injection, and one trial 14 of low risk of bias (n=48) found no difference between the two types of injection.
Midterm comparisons (13-26 weeks)
In the midterm, two studies 50 57 (both of high risk of bias) reported a significant difference in outcome favouring CS injection. One study 37 (of high risk of bias) reported a significant difference in favour of local anaesthetic injection for pain relief. The remaining two studies, 14 53 both of low risk of bias and including 217 participants, reported that there was no significant difference in midterm outcomes between the two types of injection therapy. Penning et al 53 mixed anaesthetic (lidocaine 1%) with sodium chloride (0.9%), and the effect of sodium chloride may have been a confounding influence. Of note, Penning et al 53 reported that this preparation (lidocaine and sodium chloride), designated as the placebo group in this trial, had the best results at 26 weeks with respect to reduction in pain and improvement in functional mobility.
long-term comparisons (≥1 year)
This review identified only two studies with long-term outcome measures of at least 1 year. In summary, in the long term, there is evidence from only one study 38 (high risk of bias) favouring CS injections, and one study 54 (low risk of bias, n=179) suggesting no significant difference between injection groups.
best evidence synthesis
Using the rating system described in our methods section 42 and taking into account the results from all 13 studies (both of low and high risk of bias) to provide a best evidence synthesis, we summarise the following results: ► There is strong evidence (from eight trials, three of low risk of bias) to suggest a significant benefit of CS injections over anaesthetic-only injections for the first 4-8 weeks. ► There is strong evidence (from seven trials, three of low risk of bias) to suggest that at 12 weeks there is no significant difference in outcome between injection types. ► There is strong evidence (from two trials of low risk of bias)
to suggest that there is no significant difference in outcome between injection types in the midterm (26 weeks). 
Review
► There is limited evidence (from one trial of low risk of bias) to suggest that there is no significant difference between injection types in the long term (1 year or longer). In summary, CS injections may have better short-term results than anaesthetic-only injections in the first 8 weeks. There does not appear to be any convincing evidence from the studies of low or high risk of bias that CS injections confer additional benefit over anaesthetic-only injections after this time point.
DIsCussIOn
The studies evaluated as being at low risk of bias in this review have indicated that there may be a temporary initial benefit (4-8 weeks) of administering CS in comparison with anaesthetic injections for the treatment of RCRSP. There does not appear to be any evidence that CS injections confer any additional benefit after this time point. We are unable therefore to establish whether CS medications only afford a therapeutic advantage for 4-8 weeks and no added benefit thereafter, or whether they provide an initial benefit after which time both medications are of equal value.
The certainty of any conclusions reached is challenged by the choice, appropriateness and lack of consistency of outcome measures used for the patient populations within the individual studies. Due to variation in study design and inconsistent use of primary outcome measures, we did not pool data.
Although our study differs in its primary objectives and methodology, our findings are similar to those reported in a recent review. 23 The authors of this recent review did not identify any additional evidence that was not included in our review that may have influenced our findings. The continued use of CS is suggested by the authors to be attributable to 'habit, to the underappreciation of the placebo effect, to satisfy patient desire for a physical intervention, or for simple remuneration'.
The majority of the included studies did not perform injection therapy in isolation. Although use of concurrent therapy (exercise, analgesics and NSAIDs) was varied, it was balanced within each individual trial. There is no definitive way of determining the impact of concurrent therapy in addition to the administered injections on the reported outcomes. Because of this uncertainty, the influence of an independent injection or an injection in conjunction with other therapy requires further investigation.
The majority of the investigations included in this review described the administration of local anaesthetic injections as a placebo procedure, assuming that local anaesthetic injections in the subacromial space are inert and do not provide any therapeutic benefit. However, recent evidence suggests that local anaesthetics such as lidocaine and bupivaCompleted caine may have an effect of reducing tenocyte numbers 17 58 and altering collagen organisation in tendons. 59 Increased cellularity has been associated with tendinopathy 60 61 and, if elevated, reducing tenocyte numbers may be a possible mechanism by which injection therapy may contribute to the restoration of tendon homeostasis. 6 The manner by which injections may improve symptoms remains elusive, and in addition to reducing inflammation, restoring tissue homeostasis, reducing the threat of pain and placebo, 6 it has also been suggested that the therapeutic effect of subacromial injections may be the effect of distension of the subacromial space.
14 Due to these possible chemical, biological and physical effects, the assumption that local anaesthetic injections are a true placebo is challenged and suggests their use may provide a therapeutic effect. However, this needs to be balanced by a potential deleterious effect. 59 Further research is required to determine the benefits of the medicines used in these studies compared with other medicines, other interventions, natural history and a validated placebo. The physiological effects of these interventions on the local tissues needs also to be further investigated.
Implications for practice
There is a paucity of data quantifying the number of CS injections performed annually in the UK. Limited evidence from one outpatient survey (n=2000) suggested the shoulder was the most common anatomical site of musculoskeletal injection, accounting for over a third of all injections. Seventy-two per cent of injections for the shoulder were for the stated treatment of subacromial bursitis (RCRSP). 62 Recent United Kingdom National Health Service figures reveal that almost 800 000 prescriptions of injectable CSs are dispensed nationally within primary care per year. 63 The average cost of each prescription of CS is estimated at £5.16 p, totalling a yearly national cost of over £4 000 000. The average cost of a standard dose of local anaesthetic (5 mL of 1% lidocaine) is £0.24 p. 64 We believe it is safe to assume that, while exact figures for patients with RCRSP are unknown, the cost of CS injections for this patient group is sizeable and, if local anaesthetics prove safe and effective in future research, significant cost savings could be achieved. Lidocaine-only injections Review would be over 20 times less expensive than the average cost of CS medication. Clinically, in addition to cost, is the growing concern regarding the negative effects of CS on tendon tissue. 26 27 65 It has also been suggested that the use of CS injections may detrimentally impact the course of lateral epicondyalgia. 66 This review has highlighted a lack of evidence to support the use of CS injections over local anaesthetic injections for the treatment of RCRSP after an 8-week period, which raises important issues for clinicians. Should clinicians avoid injections entirely? Should clinicians consider local anaesthetic injections for patients with RCRSP as the first choice of management, and only provide CS injections to those who do not respond to local anaesthetic? Additionally, potentially, the risks of both CS and anaesthetic-only injection outweigh the benefits, as both pharmaceutical products may damage tendon tissue. Future research is needed that compares injections of CS, local anaesthetic, saline injections, needle only (for the mechanical effect), other products (eg, hyaluronate sodium) an adviceonly group, true placebo and a control group (to map natural history). In addition, uncertainty persists over the benefit of image-guided versus landmark-guided injection therapy for the treatment of RCRSP 32 67 and whether the procedure should be performed locally or systemically. 33 In an investigation of local (CS to the subacromial bursa and local anaesthetic to the gluteal region) versus systemic (CS to the gluteal region and local anaesthetic to the subacromial bursa) for RCRSP, Ekberg et al 33 concluded that as both groups improved, both local and systemic injections of CS were equally effective. Although this may support a systemic effect of CS, these findings may be confounded for a number of reasons. This review suggests that CS injections may confer clinical benefit in the first 8 weeks, but beyond this time point both types of injections and anaesthetic injections appear to be equally effective. Therefore, the conclusion that local and systemic CS injections are equally effective 33 needs to be considered cautiously as the benefit reported in this study may have been due to the administration of CS and local anaesthetic injections to the subacromial bursa. In addition, as there was no control group, the reported findings 33 may have mapped natural improvement or possibly an equivalent placebo response in both groups.
Review
The findings of this review suggest that, in the treatment of RCRSP, CS injections may have a more beneficial effect than Review anaesthetic injections alone in the short term (up to 8 weeks). However, the size of this effect is uncertain and beyond this time point, the two medicines appear to have a comparable effect. The combination of anaesthetics and sodium chloride may be associated with better outcome at 26 weeks. 53 Anaesthetic alone may also have a positive effect in the short term. The uncertainty implies that it is not yet possible to guide clinicians on particular circumstances where (1) there is a definitive role for injection therapy for RCRSP and (2) when CS or anaesthetics may be equally responsive or one may be more beneficial than the other. Equally important is that both medicines may have a detrimental effect on rotator cuff tissue. Shared decision making empowers people seeking healthcare to voice their opinions and thoughts. The findings of this review may be used to help inform people of the risks and benefits of their choices.
lIMITATIOns
There is debate regarding how to assess risk of bias and methodological quality in clinical trials. 68 The variety of tools available, covering differing items/ domains, suggest a lack of agreement regarding their relevance. 69 The Cochrane risk of bias tool was used in this review. Although widely used, this tool does have some acknowledged challenges; these include modest inter-rater agreement and how to deal with the risk of bias associated with funding/conflicts of interest. 70 In this review, inter-rater agreement was strong with both reviewers making similar judgements regarding the importance of potential sources of bias (92.31%, Kappa score of 0.836), and conflict of interest data are presented (table 2). The assessment of risk of bias in this review was influenced by the amount of incomplete or missing information in included studies 70 (table 2) . This contributed to studies being rated as being at high risk of bias and, as the majority of studies were assessed as being at potentially high risk of bias, this limited the extent to which the objective of this review could be achieved.
Although we performed a thorough search of published literature, we did not perform a search of sources of grey literature such as conference papers or government reports. As such, we acknowledge this as a potential source of publication bias within our literature search.
COnClusIOns
CS injections may have a short-term benefit (up to 8 weeks) over local anaesthetic injections alone in the management of RCRSP. However, the certainty of this conclusion is challenged due to variations in outcome measures and study design. Beyond 8 weeks, there was no evidence to suggest a benefit of CS over local anaesthetics.
What are the findings?
► Corticosteroid injections may confer superior benefit compared with anaesthetic-only injections in the short term (up to 8 weeks). ► Beyond 8 weeks, corticosteroid and anaesthetic-only injections had the same therapeutic effect for rotator cuffrelated shoulder pain. ► It is unknown if improvement over time is due to placebo, natural history or a therapeutic effect of the medicines used in the published research.
how might it impact on clinical practice in the future?
► Both corticosteroid and anaesthetic-only injections may have short-term benefit for people considering injection therapy for rotator cuff-related shoulder pain. ► Corticosteroid injections may have a superior short-term therapeutic effect compared with anaesthetic-only injections, but not beyond that time point. ► The medium-term and long-term effects of corticosteroid and anaesthetic injections are equivocal.
